

ASX Announcement

12 November 2025

Investor Webinar Update

Mr Nathan Smith (CEO of NeuroScientific Biopharmaceuticals) to provide an overview of the recent reporting period and an update on upcoming milestones.

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) (“NSB” or the “Company”), an innovative Australian biotechnology company developing novel technologies targeted at immune-mediated inflammatory diseases, is pleased to announce it will be holding an investor webinar on Thursday, 13 November 2025 at 11:00am AEDT (8:00 AWST).

DATE/TIME: Thursday, 13 November 2025 at 11:00am AEDT

SPEAKER(S): Mr Nathan Smith (CEO)

REGISTRATION: <https://bit.ly/NSB-Nov-2025>



During the webinar, **Mr Nathan Smith (CEO)** will be providing an overview of the previous reporting period (July – September 2025) in light of the recently released Quarterly Activities Report & Appendix 4C, as well as providing a company update and overview of the anticipated upcoming milestones for the Company moving through FY2026. There will also be time for Q&A with the presenters.

Registration for the webinar is required if you would like to attend live via Zoom, as well as submit questions for the Q&A component following the presentation.

A recording will also be provided later in the day, following the webinar.

Announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

For more information, please contact:

Nathan Smith

Chief Executive Officer

NeuroScientific Biopharmaceuticals Ltd

ir@neuroscientific.com

Jane Morgan

Investor & Media Relations

Jane Morgan Management

jm@janemorganmanagement.com.au

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.

Targeting Crohn's Disease with StemSmart™ Technology

Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology through a SAS program targeting fistulising Crohn's disease—a severe and treatment-resistant form of the condition. Favourable outcomes will support the Company's progression to a Phase 2 clinical trial to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn's disease. This initiative aligns with NSB's broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn's disease, for whom current therapies remain inadequate.

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.